1 min read|49 words
Breakthrough in breast cancer treatment: A randomized phase 2 trial in Nature Medicine shows that combining durvalumab immunotherapy with stereotactic radiation produces encouraging responses in hormone-receptor-positive breast cancer—even in patients previously thought resistant to immunotherapy. Results expand treatment options beyond triple-negative disease.
Read the full article on GMJ Newsroom →
Was this article helpful?
